Software Solutions: Bridging the Gap between Public Health and Pharmacies
ID: CDC/NCHHSTP 055Type: BOTH
Overview

Topic

Software Solutions: Bridging the Gap between Public Health and Pharmacies

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: SBIRPhase: BOTHYear: 2023

Topic Link

https://www.sbir.gov/node/2451761

Additional Information

https://sam.gov/opp/aa72581c848947f0b61c15062e604862/view
Timeline
  1. 1
    Release Aug 25, 2023 12:00 AM
  2. 2
    Open Aug 25, 2023 12:00 AM
  3. 3
    Next Submission Due Nov 14, 2023 12:00 AM
  4. 4
    Close Nov 14, 2023 12:00 AM
Description

The National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) are seeking proposals for software solutions that bridge the gap between public health and pharmacies. The goal is to enable collaborative care communication, case and disease management, and reporting between health departments and pharmacy practices. The software should allow for real-time detection capabilities, treatment documentation, and the ability to send test results between pharmacists and health departments. Phase I SBIR proposals will be accepted, with a budget of up to $243,500 for up to 6 months. Phase II proposals may receive up to $1,972,828 in funding and have a duration of up to 2 years. The deadline for proposals is November 14, 2023.

Files
No associated files provided.
Similar Opportunities
NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required). This solicitation encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials, including mechanistic studies associated with clinical trials. The program supports milestone-driven, hypothesis-driven clinical trials related to the research mission of the NIAID that address high-priority research areas. The solicitation encourages high-risk clinical studies, which involve non-routine interventions, administration of an unlicensed product, or administration of a licensed product for an unapproved indication. Mechanistic studies are also encouraged. The funding supports the conduct, completion, and analysis of a single clinical trial, including activities such as training of study personnel, enrollment and recruitment of study subjects, data collection and management, laboratory work, safety monitoring, and regulatory activities. The project duration is not specified, but the application due dates are provided. More information can be found on the grants.gov website.
SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development. This program aims to provide additional support for later stage research and development (R&D) and product development not typically supported through Phase II or Phase IIB grants or contracts. The program is designed to bridge the funding gap between the end of the SBIR/STTR Phase II award and the commercialization stage, often referred to as the "Valley of Death." The program supports projects that require technical assistance and R&D studies typically outsourced to contract research organizations (CROs), such as regulatory assistance, IND/IDE enabling studies, toxicology, manufacturing, and clinical trials. The program also supports activities important for commercialization, such as product development, market planning, market research, and costs related to license agreements and partnerships. The program is open to companies that have received Phase II or Phase IIB funding from NIH within the last 36 months. The application due dates are September 5, 2023, January 5, 2024, April 5, 2024, September 5, 2024, January 5, 2025, and April 5, 2025. For more information and to apply, visit the solicitation agency URL: [link](https://grants.nih.gov/grants/guide/PA-files/PAR-23-220.html).
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by Opioid and/or Stimulants use Disorders (OUD/StUD). The current drug crisis involving opioids and stimulants has resulted in a significant number of deaths and a need for comprehensive solutions. This funding opportunity aims to support research and development activities for novel medical products that address the needs of patients suffering from OUD/StUD. The two areas of focus for this solicitation are pharmacotherapeutics (small molecules and biologics) and medical therapeutic and diagnostic devices, including software as a medical device. The research topics may include the development of new medications, longer-acting formulations, advanced drug delivery systems, biomarkers, imaging technologies, therapeutic devices, in vitro diagnostic assays, and digital therapeutics. The projects proposed under this solicitation may fall under Phase I, Phase II, Fast Track, or Direct to Phase II categories. The funding opportunity is open until February 15, 2025. For more information and to apply, visit the grants.gov website or the National Institutes of Health's solicitation agency URL.
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by opioid and/or stimulants use disorders (OUD/StUD). The current drug crisis involving opioids and stimulants has resulted in a significant number of deaths and a need for comprehensive solutions. This funding opportunity aims to support research and development activities for novel medical products that address the needs of patients suffering from OUD/StUD. The two areas of focus are pharmacotherapeutics (small molecules, biologics, natural products, etc.) and medical therapeutic and diagnostic devices (imaging technologies, therapeutic devices, diagnostic assays, etc.). The projects proposed should aim to establish technical feasibility, commercial potential, and the quality of performance of the small business awardee organization. The funding opportunity includes Phase I, Phase II, Fast Track, and Direct to Phase II applications. The deadline for applications is February 15, 2025. For more information and to apply, visit the grants.gov website or the solicitation agency URL provided.
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of technologies to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder. The purpose of this funding opportunity is to support small business concerns in developing technologies for commercialization that can fill the service gaps in addressing SUD. The research objectives include developing products that reduce costs, time, and increase access in addressing health-related social needs such as housing instability, non-medical transportation, food insecurity, utility needs, and personal safety. The technologies can include physical devices, digital services, software, or non-physical/non-tangible products. The funding opportunity is open for applications until March 14, 2026, and offers both Phase I and Phase II funding options. Phase I focuses on establishing technical merit and feasibility, while Phase II aims to advance technologies towards commercialization. Applicants are encouraged to review the guidelines and adhere to the requirements applicable to their research.